查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990350

Dravet症候群市场：2026-2032年全球市场预测（依药物类别、给药途径、病患年龄层、最终用户和分销管道划分）

Dravet Syndrome Market by Drug Class, Route Of Administration, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年 Dravet 症候群市场价值为 8.008 亿美元，预计到 2026 年将成长至 8.6596 亿美元，复合年增长率为 8.97%，到 2032 年将达到 14.5989 亿美元。

主要市场统计数据
基准年 2025 8.008亿美元
预计年份：2026年 8.6596亿美元
预测年份：2032年 1,459,890,000 美元
复合年增长率 (%) 8.97%

全面而以临床为基础的德拉韦综合征介绍，重点关注诊断方面的进展、治疗的复杂性以及医疗保健服务不断变化的挑战。

Dravet症候群是一种罕见的严重癫痫性脑病变，通常在婴儿期发病，其特征是长期、难治性癫痫发作和进行性神经发育障碍。临床治疗复杂，需要多学科协作，神经科医生、急诊科医生、癫痫专科中心和家庭看护者之间必须密切配合。近年来，由于早期基因检测和对该疾病表型多样性认识的提高，诊断准确率有所提高，但许多患者仍然饱受严重癫痫发作和严重合併症的困扰，存在未被满足的医疗需求。

确定临床、监管和数位领域中各种因素的整合，这些因素从根本上改变了 Dravet 症候群的治疗管道、治疗途径和相关人员的优先事项。

围绕德拉韦氏症候群的格局正在发生多方面的变革，这些变革正在重塑临床治疗、研究重点和商业策略。在临床层面，早期基因诊断和以表型为基础的治疗方法选择使得更个人化的治疗方案成为可能，而癫痫专科网路的成熟则集中了专业知识并改善了长期照护的协调性。同时，药理学的进步正在丰富治疗选择，人们重新关注针对离子通道功能、GABA能调节和神经调节通道的不同类型药物。

了解不断变化的美国关税政策对供应链、筹资策略以及获得德拉韦综合征治疗的途径所产生的累积营运和商业影响。

到2025年，美国关税趋势将进一步增加德拉韦综合征相关产业链中製造商、经销商和医疗保健机构的营运复杂性。影响进口药品活性成分、某些医疗设备和包装组件的关税正在推高上游投入成本，迫使许多企业重新评估其供应链的韧性。拥有全球製造地的公司被迫评估其产品的总到岸成本，并考虑将关键生产流程转移到国内或近岸地区，以降低贸易政策波动的风险。

整合药物类别、医疗保健环境、分销管道、给药途径和年龄层等临床要求，可提供详细的见解来指南您的策略。

细分市场分析揭示了不同药物类别、终端使用者、分销管道、给药途径和患者年龄组在临床和商业性趋势上的差异。在药物类别细分方面，大麻素类药物持续受到关注，其治疗效果主要集中在大麻二酚和四氢大麻酚等次成分。同时，包括Clobazam、Diazepam和司替戊醇在内的GABA调变器在辅助性治疗和抢救治疗中继续发挥核心作用。包括托吡酯类和丙戊酸在内的钠通道阻断剂对某些类型的癫痫仍然有效，这些药物相对良好的安全性和耐受性指南医生选择药物和联合治疗策略。

全面深入的临床和商业性见解，涵盖北美、南美、欧洲、中东、非洲和亚太地区的准入现实、监管差异和医疗保健基础设施，并对区域差异提供细緻入微的见解。

区域趋势对德拉韦症候群的临床实践、法规环境和商业性机会有显着影响。在美洲，相关人员受益于成熟的专业医疗网络、先进的基因诊断基础设施以及不断发展的支付模式，这些模式越来越重视能够证明临床和功能显着改善的证据。然而，医疗服务取得仍面临挑战，尤其是在农村和资源匮乏地区，这些地区专业的癫痫中心稀少，远端保健的实施情况也因支付方政策而异。

策略商业环境分析重点阐述了大型製药企业、创新生物技术公司、学术机构和服务供应商的综合能力如何决定竞争地位。

Dravet症候群的生态系统涉及多种企业和机构活动，包括成熟的製药公司、专业的生物技术公司、学术机构、契约製造组织（CMO）和专科药房，各方发挥互补作用。老字型大小企业通常主导后期研发和大规模生产，拥有完善的商业基础设施，能够支援与支付方进行复杂的谈判并建立广泛的分销网络。专业的生物技术公司则经常透过标靶作用机制和新型製剂推动创新，推动早期临床治疗方法，并透过策略合作拓展业务。

针对患有 Dravet 症候群的利害关係人的具体需求，提出切实可行且有影响力的产品开发、供应链优化和支付方参与建议。

行业领导者应推动一系列切实可行、以证据为基础的倡议，将科学进步转化为可持续的患者获益和商业性成功。首先，应优先考虑与监管机构和支付方进行早期且持续的合作，使证据生成与报销要求相符，并製定能够满足儿童安全性和有效性终点的适应性开发计划。其次，应投资于诊断基础设施和基因检测伙伴关係，以加速早期精准诊断，从而改善临床试验的患者招募，并在实际临床实践中选择合适的治疗标靶。

我们透过透明的混合方法调查方法，结合临床证据审查、专家访谈和用例分析，产生可操作且检验的见解。

本分析的调查方法结合了严谨的证据整合和有针对性的相关人员参与，以确保其相关性和可靠性。主要资讯来源包括对同行评审的临床文献、监管指导文件和临床实验室註册资讯进行系统性回顾，以了解治疗机制、安全性概况和实验室设计。次要资讯来源利用公开的政策文件、支付方相关文件、技术白皮书和临床实践指南，以阐明准入管道和临床应用趋势。此外，还对神经科、癫痫专家、专科药剂师和卫生经济学专家进行了访谈，以检验解释性见解并识别文献中未总是明确提及的实际考虑因素。

具有前瞻性的结论整合了临床进展、营运挑战以及为改善 Dravet 症候群患者的护理和就医所必需的协作策略。

总之，应对德拉韦症候群复杂的临床和商业性挑战，需要在诊断、治疗和医疗服务可近性等各个领域采取协调一致的方法。基因诊断技术的进步和治疗手段的多样化为改善癫痫控制和发育结果创造了新的机会，但要实现这些益处，需要结构完善的循证策略、健全的价值链以及与支付方一致的价值证明。向远端保健和以专科医生为中心的医疗模式的转变为扩大医疗服务可及性提供了途径，但仍然存在差距，需要在地方和区域层面采取有针对性的干预措施。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：德拉韦氏症候群市场：依药物类别划分

  • 大麻素
    • CBD
    • THC
  • GABA调变器
    • Clobazam
    • Diazepam
    • 司替戊醇
  • 钠通道阻断剂
    • 托吡酯
    • 丙戊酸

第九章：德拉韦氏症候群药物市场：依给药途径划分

  • 注射药物
  • 鼻喷剂
  • 口服
  • 口腔黏膜
  • 经皮

第十章：德拉韦症候群市场：依患者年龄组别划分

  • 青年
  • 成人
  • 儿童
  • 婴儿

第十一章：德拉韦症候群市场：以最终用户划分

  • 居家照护
  • 医院
  • 癫痫专科中心

第十二章：德拉韦氏症候群市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：德拉韦症候群市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：德拉韦氏症候群市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：德拉韦氏症候群市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国德拉韦症候群市场

第十七章：中国的德拉韦氏症候群市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Biogen Inc.
  • Eisai Co., Ltd.
  • Encoded Therapeutics, Inc.
  • Epygenix Therapeutics, Inc.
  • GW Pharmaceuticals plc
  • Jazz Pharmaceuticals plc
  • Longboard Pharmaceuticals, Inc.
  • Marinus Pharmaceuticals, Inc.
  • Neuroelectrics BC
  • PTC Therapeutics, Inc.
  • Radiopharm Theranostics, LLC
  • Stoke Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • UCB SA
  • Zogenix, Inc.
Product Code: MRR-4D00F1312C81

The Dravet Syndrome Market was valued at USD 800.08 million in 2025 and is projected to grow to USD 865.96 million in 2026, with a CAGR of 8.97%, reaching USD 1,459.89 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 800.08 million
Estimated Year [2026] USD 865.96 million
Forecast Year [2032] USD 1,459.89 million
CAGR (%) 8.97%

A comprehensive and clinically grounded introduction to Dravet syndrome emphasizing diagnostic advances, therapeutic complexity, and evolving care delivery imperatives

Dravet syndrome represents a rare, severe epileptic encephalopathy with onset in infancy, characterized by prolonged, treatment-resistant seizures and progressive neurodevelopmental impairment. Clinical management is complex and multidisciplinary, requiring careful coordination between neurology, emergency medicine, specialty epilepsy centers, and home-based caregivers. Recent years have seen advances in diagnostic precision through earlier genetic testing and improved recognition of the condition's phenotypic heterogeneity, yet many patients continue to experience high seizure burden and profound comorbidities that drive unmet clinical needs.

This introduction frames the landscape in terms of evolving therapeutic modalities, care delivery shifts, and commercial implications. It emphasizes the interplay between novel pharmacologic strategies targeting specific pathophysiologic mechanisms, supportive and rescue interventions for acute events, and the critical role of specialized care settings. The narrative also highlights how payer policies, distribution pathways, and patient age segmentation shape access and adherence. By situating Dravet syndrome within contemporary clinical practice and policy trends, the section primes stakeholders to evaluate opportunities across drug classes, routes of administration, and care delivery innovations while remaining attuned to the ethical and regulatory complexities that accompany treatments for pediatric populations.

Identifying the convergent clinical, regulatory, and digital forces that are fundamentally transforming treatment pathways, therapy access, and stakeholder priorities in Dravet syndrome

The landscape for Dravet syndrome is shifting along multiple transformative vectors that are reshaping clinical care, research priorities, and commercial strategies. At the clinical level, earlier genetic diagnosis and phenotype-driven treatment selection are enabling more personalized therapeutic approaches, while the maturation of epilepsy specialty networks is concentrating expertise and improving longitudinal care coordination. Concurrently, advances in pharmacology have diversified the treatment palette, bringing renewed attention to distinct drug classes that target ion channel function, GABAergic modulation, and neuromodulatory pathways.

On the commercial front, digital health tools and telemedicine have expanded care touchpoints and facilitated remote monitoring, thereby altering traditional patterns of utilization across hospitals, specialty centers, and home care. Distribution channel innovation-spanning hospital pharmacies to specialty and online pharmacies-has reconfigured access pathways for high-cost therapies and acute rescue medications. At the same time, regulatory and reimbursement environments are evolving to address the specific needs of rare pediatric disorders, prompting manufacturers to prioritize evidence generation strategies that demonstrate both clinical benefit and real-world impact. Together, these shifts present a new set of opportunities and constraints for stakeholders seeking to advance therapeutic options while ensuring equitable access and sustainable reimbursement.

Understanding the cumulative operational and commercial consequences of evolving United States tariff policies on supply chains, procurement strategies, and access to Dravet syndrome therapies

In 2025, United States tariff dynamics have introduced an additional layer of operational complexity for manufacturers, distributors, and providers engaged in the Dravet syndrome ecosystem. Tariffs that affect imported active pharmaceutical ingredients, certain medical devices, and packaging components have increased upstream input costs and prompted many organizations to re-evaluate supply chain resilience. Firms with global manufacturing footprints have been compelled to assess the total landed cost of goods and to consider options for onshoring or nearshoring critical production steps to mitigate exposure to trade policy volatility.

These supply-side pressures interact with distribution practices in meaningful ways. Specialty pharmacies and hospital procurement groups are adapting contracting strategies to absorb or pass through incremental costs, with implications for inventory management, formulary placement negotiations, and patient out-of-pocket liability. Payers and integrated delivery networks are increasingly scrutinizing cost drivers and may demand enhanced pharmacoeconomic evidence or value-based contracting arrangements to justify coverage of higher-cost therapies. Additionally, tariff-induced changes in component sourcing have accelerated interest in manufacturing partnerships and consolidation among smaller biotechs that lack vertical integration. Overall, the cumulative effect of tariffs is to increase the importance of proactive supply chain planning, transparent cost modeling, and strategic engagement with procurement stakeholders to preserve access and commercial viability.

Deep segmentation-driven insights that synthesize drug class, care setting, distribution pathways, administration routes, and age-group specific clinical imperatives to guide strategy

Segmentation insights reveal differentiated clinical and commercial dynamics across drug classes, end users, distribution channels, routes of administration, and patient age groups. Within drug class segmentation, cannabinoids have garnered sustained interest with therapeutic activity concentrated in cannabidiol and tetrahydrocannabinol subcomponents, while GABA modulators encompass agents such as clobazam, diazepam, and stiripentol that remain central to adjunctive and rescue strategies. Sodium channel blockers, including agents like topiramate and valproate, continue to be relevant for certain seizure phenotypes, and the comparative safety and tolerability profiles of these classes inform prescriber choice and polytherapy strategies.

End user segmentation underscores distinct care delivery pathways: home care settings are increasingly important for long-term maintenance regimens and rescue medication administration, hospitals remain the locus for acute management and complex diagnostics, and specialty epilepsy centers provide concentrated expertise for refractory cases and surgical evaluations. Distribution channel segmentation shapes access modalities and patient experience, as hospital pharmacies, online pharmacies, retail pharmacies, and specialty pharmacies each present different operational and reimbursement interfaces that can affect initiation and continuity of therapy. Route of administration is another critical axis of differentiation; injectable and nasal routes are prioritized for rapid rescue intervention, oral and oromucosal forms support chronic management, and transdermal approaches are being explored for adherence and tolerability benefits. Patient age group segmentation highlights the spectrum of clinical needs across adolescents, adults, children, and infants, with infants and young children requiring tailored dosing, formulation considerations, and heightened safety monitoring. Integrating these segmentation lenses is essential for designing clinical development programs, market access strategies, and patient support services that align with real-world care pathways.

Regionally nuanced clinical and commercial insights that map access realities, regulatory differences, and care infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on clinical practice, regulatory environments, and commercial opportunity for therapies addressing Dravet syndrome. In the Americas, stakeholders benefit from established specialty care networks, advanced genetic diagnostics infrastructure, and evolving payer models that are increasingly receptive to evidence demonstrating meaningful clinical and functional gains. Access challenges persist, however, particularly in rural and under-resourced communities where specialty epilepsy centers are scarce and telehealth adoption varies by payer policy.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and payer systems that require tailored market entry strategies; centralized approvals and national reimbursement negotiations can lead to divergent timelines and formulary outcomes across countries. Countries with strong rare disease programs and coordinated registries show faster uptake of innovative therapies, while others face infrastructure and funding constraints that limit access. Asia-Pacific is characterized by rapid adoption of diagnostic technologies in some markets and variable reimbursement pathways across others. Local manufacturing and procurement policies, as well as differing regulatory expectations for pediatric data, shape clinical adoption and commercial pathways. Across all regions, meaningful engagement with patient advocacy groups, investment in provider education, and alignment with local clinical guidelines remain critical to improving diagnosis, treatment initiation, and long-term management outcomes.

Strategic company landscape analysis highlighting how integrated capabilities across big pharma, biotech innovators, academic centers, and service providers determine competitive positioning

Corporate and institutional activity in the Dravet syndrome ecosystem reflects a mix of established pharmaceutical companies, specialty biotechs, academic centers, contract manufacturing organizations, and specialty pharmacies, each playing complementary roles. Established companies often drive late-stage development and large-scale manufacturing capacity, and they have the commercial infrastructure to support complex payer negotiations and broad distribution networks. Specialty biotechs contribute innovation through targeted mechanisms of action and novel formulations, frequently advancing therapies through earlier-phase trials and leveraging strategic partnerships to scale.

Academic medical centers and epilepsy clinics contribute critical real-world data, investigator-initiated studies, and natural history registries that inform both clinical development and health technology assessment. Contract manufacturing organizations and specialty pharmacies provide operational capabilities to manage orphan and pediatric product demands, including specialized compounding, cold chain logistics, and patient support services. Across this landscape, cross-sector collaboration is increasingly common, combining scientific expertise, clinical credibility, and distribution know-how to accelerate translation from bench to bedside. Companies that can integrate strong clinical evidence generation with sophisticated access strategies and robust patient support programs are positioned to lead in this therapeutic area.

Actionable, high-impact recommendations for product development, supply chain optimization, and payer engagement tailored to the unique demands of Dravet syndrome stakeholders

Industry leaders should pursue a set of pragmatic, evidence-focused actions to convert scientific advances into sustainable patient benefit and commercial success. First, prioritize early and continuous engagement with regulatory authorities and payers to align evidence generation with reimbursement requirements and to design adaptive development plans that accommodate pediatric safety and efficacy endpoints. Second, invest in diagnostic infrastructure and genetic testing partnerships to accelerate accurate early diagnosis, which in turn improves trial recruitment and real-world treatment targeting.

Third, reinforce supply chain resilience by diversifying sourcing of critical inputs, exploring nearshoring for selected manufacturing steps, and formalizing contingency plans to address tariff or trade disruptions. Fourth, develop differentiated distribution strategies that leverage specialty pharmacies for high-touch support, hospital pharmacies for acute care pathways, and online channels to reach geographically dispersed patient populations, with tailored adherence and education programs. Fifth, design age-appropriate formulations and administration routes that reflect the clinical realities of infants, children, adolescents, and adults, thereby enhancing tolerability and adherence. Finally, cultivate partnerships with specialty epilepsy centers and patient advocacy organizations to co-develop registries and real-world evidence initiatives that substantiate long-term outcomes and value, enabling more credible conversations with payers and health systems.

A transparent mixed-methods research methodology integrating clinical evidence review, expert interviews, and case study analysis to produce actionable and validated insights

The research methodology underpinning this analysis combines rigorous evidence synthesis with targeted stakeholder engagement to ensure relevance and credibility. Primary inputs include systematic review of peer-reviewed clinical literature, regulatory guidance documents, and clinical trial registries to capture therapeutic mechanisms, safety profiles, and trial designs. Secondary inputs draw on publicly available policy and payer documentation, technical white papers, and practice guidelines to contextualize access pathways and clinical adoption trends. Expert interviews with neurologists, epileptologists, specialty pharmacists, and health economics specialists were conducted to validate interpretive findings and to surface practical operational considerations not always explicit in the literature.

Qualitative thematic analysis and cross-validation of findings ensured consistency across data sources, while case study reviews of recent therapeutic launches provided real-world illustrations of commercialization challenges and successful strategies. The methodology emphasized transparency, with clear documentation of source types, interviewee roles, and analytical assumptions. Wherever possible, findings were triangulated across multiple sources to bolster reliability. This mixed-methods approach balances depth of clinical insight with practical commercial intelligence, providing stakeholders with actionable knowledge grounded in both evidence and frontline experience.

A forward-looking conclusion that synthesizes clinical progress, operational imperatives, and collaborative strategies necessary to improve care and access for Dravet syndrome patients

In conclusion, addressing the complex clinical and commercial challenges of Dravet syndrome requires coordinated efforts across diagnostic, therapeutic, and access domains. Advances in genetic diagnosis and diversifying therapeutic classes are creating new opportunities to improve seizure control and developmental trajectories, but realizing these benefits hinges on thoughtful evidence strategies, resilient supply chains, and payer-aligned value demonstration. Care delivery shifts toward telehealth and specialty-centric models offer avenues to expand access, yet disparities remain that demand targeted interventions at the regional and local levels.

Stakeholders who integrate precision diagnosis, age-appropriate formulation development, and robust patient support while engaging payers proactively will be best positioned to translate scientific progress into sustained clinical impact. Collaborative models that bring together industry, clinicians, and patient advocates to co-create registries and real-world evidence programs will strengthen the case for coverage and reimbursement. The path forward is pragmatic: combine scientific rigor with operational excellence and stakeholder alignment to deliver meaningful improvements for patients living with Dravet syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dravet Syndrome Market, by Drug Class

  • 8.1. Cannabinoids
    • 8.1.1. CBD
    • 8.1.2. THC
  • 8.2. Gaba Modulators
    • 8.2.1. Clobazam
    • 8.2.2. Diazepam
    • 8.2.3. Stiripentol
  • 8.3. Sodium Channel Blockers
    • 8.3.1. Topiramate
    • 8.3.2. Valproate

9. Dravet Syndrome Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Nasal
  • 9.3. Oral
  • 9.4. Oromucosal
  • 9.5. Transdermal

10. Dravet Syndrome Market, by Patient Age Group

  • 10.1. Adolescents
  • 10.2. Adults
  • 10.3. Children
  • 10.4. Infants

11. Dravet Syndrome Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital
  • 11.3. Specialty Epilepsy Centers

12. Dravet Syndrome Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Dravet Syndrome Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dravet Syndrome Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dravet Syndrome Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Dravet Syndrome Market

17. China Dravet Syndrome Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Biogen Inc.
  • 18.6. Eisai Co., Ltd.
  • 18.7. Encoded Therapeutics, Inc.
  • 18.8. Epygenix Therapeutics, Inc.
  • 18.9. GW Pharmaceuticals plc
  • 18.10. Jazz Pharmaceuticals plc
  • 18.11. Longboard Pharmaceuticals, Inc.
  • 18.12. Marinus Pharmaceuticals, Inc.
  • 18.13. Neuroelectrics BC
  • 18.14. PTC Therapeutics, Inc.
  • 18.15. Radiopharm Theranostics, LLC
  • 18.16. Stoke Therapeutics, Inc.
  • 18.17. Takeda Pharmaceutical Company Limited
  • 18.18. UCB S.A.
  • 18.19. Zogenix, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GCC DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GCC DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. G7 DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. G7 DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. G7 DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. NATO DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 208. NATO DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. NATO DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. NATO DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA DRAVET SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)